Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2026)

Gilead Sciences (GILD) has 5 years of Asset Writedowns and Impairment data on file, last reported at $400.0 million in Q4 2025.

• Quarterly Asset Writedowns and Impairment rose 1900.0% year-over-year to $400.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $590.0 million (down 86.02% YoY) and the FY2025 annual result came in at $590.0 million, down 85.95% from the prior year.
• Asset Writedowns and Impairment climbed to $400.0 million in Q4 2025, from $190.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $2.7 billion in Q1 2022 to a low of $20.0 million in Q4 2024.
• A 4-year average of $1.1 billion and a median of $400.0 million in 2025 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 60.0% — and 2025, when it jumped 1900.0%.
• Tracing GILD's Asset Writedowns and Impairment over 4 years: stood at $2.7 billion in 2022, then slumped by 98.15% to $50.0 million in 2023, then slumped by 60.0% to $20.0 million in 2024, then jumped by 1900.0% to $400.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $400.0 million (Q4 2025), $190.0 million (Q2 2025), and $20.0 million (Q4 2024), per Business Quant data.